Comparable stake leader
FMR LLC
SEC ownership of Moderna, Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001682852.
Disclosed value leader
FMR LLC
Comparable rows
50/50
Latest evidence
31 Mar 2026
- Public ticker
- MRNA on Nasdaq
- Parsed ownership sources
- 13F and 13D/G
- Largest SEC-reported holder
- FMR LLC
- Latest 13D/G holder
- FMR LLC
- Latest parsed ownership date
- 31 Mar 2026
- Issuer CIK
- 0001682852
- Issuer location
- Cambridge, MA
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
2 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of Moderna, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
FMR LLC
Disclosed value leader
FMR LLC
Comparable rows
50/50
Latest evidence
31 Mar 2026
13F
13D/G
Lead comparable stake: 11%
13D/G row: FMR LLC
Showing 1-8 of 50 holder rows.
Quick read
FMR LLC leads the comparable SEC ownership view at 11%.
50 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens FMR LLC's linked filing trail.
Comparable ownership
Top 5
FMR LLC
11%
VANGUARD CAPITAL MANAGEMENT LLC
6.5%
BAILLIE GIFFORD & CO
5.3%
BlackRock, Inc.
7.5%
Capital World Investors
4.7%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 50 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| FMR LLC |
13F
13D/G
Company
|
11%
from 13D/G
|
$2,320,138,832
45,672,024 shares
|
— | 31 Mar 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC |
13D/G
13F
Vanguard Capital Management · Company
|
6.5%
|
$1,317,438,259
25,933,824 shares
|
$0 | 31 Mar 2026 |
| BAILLIE GIFFORD & CO |
13F
13D/G
Company
|
5.3%
from 13D/G
|
$1,015,282,501
19,985,876 shares
|
— | 31 Mar 2026 |
| BlackRock, Inc. |
13F
Company
|
7.5%
|
$1,505,502,493
29,635,876 shares
|
— | 31 Mar 2026 |
| Capital World Investors |
13F
Company
|
4.7%
|
$949,814,890
18,697,694 shares
|
— | 31 Mar 2026 |
| VANGUARD PORTFOLIO MANAGEMENT LLC |
13F
Company
|
3.9%
|
$793,311,444
15,616,367 shares
|
— | 31 Mar 2026 |
| STATE STREET CORP |
13F
Company
|
3.7%
|
$754,959,577
14,861,409 shares
|
— | 31 Mar 2026 |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
Company
|
2.4%
|
$478,491,677
9,435,132 shares
|
— | 31 Mar 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to selling over the last 12 months. Net value: -$12,547,131.
Buys
$0
Insiders: 0
Sells
$12,547,131
Insiders: 4
Net
-$12,547,131
Shares: -266,844
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 266,844
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 68,281 | $0 | $3,280,293 | -$3,280,293 |
| 3-6 | 0 | 198,251 | $0 | $9,258,102 | -$9,258,102 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 312 | $0 | $8,736 | -$8,736 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-20 of 21 reporting-owner rows connected to Moderna, Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
21
Largest Forms 3/4/5 holder
Stephane Bancel
Net 12M change
-$12,547,132
Latest report
01 Jun 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Stephane Bancel | Chief Executive Officer, Director | $511,509,633 | Mixed | 01 Mar 2026 | ||
| Ph.D. Noubar B. Afeyan | Director | $348,393,290 | -$1,137,185 | -0.33% | Mixed | 21 May 2026 |
| Stephen Hoge | President | $87,924,377 | -$10,396,302 | -11% | Mixed | 01 Jun 2026 |
| Paul Sagan | Director | $15,693,665 | Mixed | 30 Apr 2025 | ||
| Shannon Thyme Klinger | Chief Legal Officer | $3,463,287 | -$726,047 | -17% | Mixed | 01 Jun 2026 |
| James M. Mock | Chief Financial Officer | $3,326,368 | Mixed | 01 Jun 2026 | ||
| Stephen Berenson | Director | $2,517,789 | Mixed | 03 May 2024 | ||
| Francois Nader | Director | $1,665,274 | Median | 06 May 2026 | ||
| Arpa Garay | Chief Commercial Officer | $1,524,005 | Mixed | 05 Dec 2023 | ||
| Juan Andres | Chief Technical Operations and Quality Officer | $1,330,232 | Mixed | 28 Dec 2022 | ||
| Elizabeth G. Nabel | Director | $1,092,320 | Mixed | 06 May 2026 | ||
| Sandra Horning | Director | $1,055,135 | Mixed | 06 May 2026 | ||
| David W. Meline | Chief Financial Officer | $645,077 | Mixed | 09 Aug 2022 | ||
| Abbas Hussain | Director | $628,264 | -$287,598 | -31% | Mixed | 06 May 2026 |
| David M. Rubenstein | Director | $572,203 | Mixed | 06 May 2026 | ||
| Paul Burton | Chief Medical Officer | $541,865 | Mixed | 04 Nov 2022 | ||
| Elizabeth E. Tallett | Director | $241,858 | Median | 06 May 2026 | ||
| Lori M. Henderson | General Counsel and Secretary | $93,614 | Mixed | 27 May 2021 | ||
| Tal Zvi Zaks | Chief Medical Officer | Mixed | 30 Jun 2021 | |||
| Robert Langer | Director | Mixed | 06 May 2024 |
Recent insider transactions for Moderna, Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| James M. Mock | MRNA | Common Stock | Tax liability | -1.97% | -1,197 | 59,594 | 01 Jun 2026 | Direct | ||
| James M. Mock | MRNA | Common Stock | Options Exercise | 4.24% | 2,475 | 60,791 | 01 Jun 2026 | Direct | ||
| James M. Mock | MRNA | Restricted Stock Units | Options Exercise | -8.33% | -2,475 | 27,230 | 01 Jun 2026 | Direct | ||
| Shannon Thyme Klinger | MRNA | Common Stock | Tax liability | -1.53% | -1,047 | 67,468 | 01 Jun 2026 | Direct | ||
| Shannon Thyme Klinger | MRNA | Common Stock | Options Exercise | 3.26% | 2,165 | 68,515 | 01 Jun 2026 | Direct | ||
| Shannon Thyme Klinger | MRNA | Restricted Stock Units | Options Exercise | -8.33% | -2,165 | 23,827 | 01 Jun 2026 | Direct | ||
| Stephen Hoge | MRNA | Common Stock | Tax liability | -0.3% | -4,488 | 1,483,848 | 01 Jun 2026 | Direct | ||
| Stephen Hoge | MRNA | Common Stock | Options Exercise | 0.63% | 9,282 | 1,488,336 | 01 Jun 2026 | Direct | ||
| Stephen Hoge | MRNA | Restricted Stock Units | Options Exercise | -8.33% | -9,282 | 102,111 | 01 Jun 2026 | Direct | ||
| James M. Mock | MRNA | Common Stock | Tax liability | -0.27% | -159 | 58,316 | 28 May 2026 | Direct | ||
| James M. Mock | MRNA | Common Stock | Options Exercise | 0.56% | 328 | 58,475 | 28 May 2026 | Direct | ||
| James M. Mock | MRNA | Restricted Stock Units | Options Exercise | -24.9% | -328 | 987 | 28 May 2026 | Direct | ||
| Shannon Thyme Klinger | MRNA | Common Stock | Tax liability | -0.24% | -159 | 66,350 | 28 May 2026 | Direct | ||
| Shannon Thyme Klinger | MRNA | Common Stock | Options Exercise | 0.5% | 328 | 66,509 | 28 May 2026 | Direct | ||
| Shannon Thyme Klinger | MRNA | Restricted Stock Units | Options Exercise | -24.9% | -328 | 987 | 28 May 2026 | Direct | ||
| Stephen Hoge | MRNA | Common Stock | Tax liability | -0.02% | -295 | 1,479,054 | 28 May 2026 | Direct | ||
| Stephen Hoge | MRNA | Common Stock | Options Exercise | 0.04% | 610 | 1,479,349 | 28 May 2026 | Direct | ||
| Stephen Hoge | MRNA | Restricted Stock Units | Options Exercise | -25% | -610 | 1,832 | 28 May 2026 | Direct | ||
| James M. Mock | MRNA | Common Stock | Tax liability | -0.64% | -374 | 58,147 | 27 May 2026 | Direct | ||
| James M. Mock | MRNA | Common Stock | Options Exercise | 1.34% | 773 | 58,521 | 27 May 2026 | Direct | ||
| James M. Mock | MRNA | Restricted Stock Units | Options Exercise | -12.5% | -773 | 5,416 | 27 May 2026 | Direct | ||
| Shannon Thyme Klinger | MRNA | Common Stock | Tax liability | -0.56% | -374 | 66,181 | 27 May 2026 | Direct | ||
| Shannon Thyme Klinger | MRNA | Common Stock | Options Exercise | 1.18% | 773 | 66,555 | 27 May 2026 | Direct | ||
| Shannon Thyme Klinger | MRNA | Restricted Stock Units | Options Exercise | -12.5% | -773 | 5,416 | 27 May 2026 | Direct | ||
| Stephen Hoge | MRNA | Common Stock | Tax liability | -0.05% | -695 | 1,478,739 | 27 May 2026 | Direct | ||
| Stephen Hoge | MRNA | Common Stock | Options Exercise | 0.1% | 1,437 | 1,479,434 | 27 May 2026 | Direct | ||
| Stephen Hoge | MRNA | Restricted Stock Units | Options Exercise | -12.5% | -1,437 | 10,058 | 27 May 2026 | Direct | ||
| Ph.D. Noubar B. Afeyan | MRNA | Common Stock | Sale | -70.2% | $433,879 | $46.84 | -9,263 | 3,924 | 21 May 2026 | By Flagship Pioneering, LLC |
| Ph.D. Noubar B. Afeyan | MRNA | Common Stock | Options Exercise | 236.1% | 9,263 | 13,187 | 21 May 2026 | By Flagship Pioneering, LLC | ||
| Ph.D. Noubar B. Afeyan | MRNA | Stock Option (Right to Buy) | Options Exercise | -100% | -9,263 | 0 | 21 May 2026 | By Flagship Pioneering, LLC | ||
| Stephen Hoge | MRNA | Common Stock | Sale | -3.48% | $2,581,462 | $48.40 | -53,336 | 1,477,997 | 15 May 2026 | Direct |
| Stephen Hoge | MRNA | Common Stock | Options Exercise | 3.61% | 53,336 | 1,531,333 | 15 May 2026 | Direct | ||
| Stephen Hoge | MRNA | Stock Option (Right to Buy) | Options Exercise | -62.3% | -53,336 | 32,220 | 15 May 2026 | Direct | ||
| David M. Rubenstein | MRNA | Restricted Stock Units | Award | 2,092 | 2,092 | 06 May 2026 | Direct | |||
| David M. Rubenstein | MRNA | Stock Option (Right to Buy) | Award | 9,681 | 9,681 | 06 May 2026 | Direct | |||
| Abbas Hussain | MRNA | Restricted Stock Units | Award | 8,371 | 8,371 | 06 May 2026 | Direct | |||
| Sandra Horning | MRNA | Restricted Stock Units | Award | 2,092 | 2,092 | 06 May 2026 | Direct | |||
| Sandra Horning | MRNA | Stock Option (Right to Buy) | Award | 9,681 | 9,681 | 06 May 2026 | Direct | |||
| Elizabeth G. Nabel | MRNA | Restricted Stock Units | Award | 8,371 | 8,371 | 06 May 2026 | Direct | |||
| Francois Nader | MRNA | Restricted Stock Units | Award | 4,185 | 4,185 | 06 May 2026 | Direct | |||
| Francois Nader | MRNA | Stock Option (Right to Buy) | Award | 6,454 | 6,454 | 06 May 2026 | Direct | |||
| Elizabeth E. Tallett | MRNA | Restricted Stock Units | Award | 8,371 | 8,371 | 06 May 2026 | Direct | |||
| Noubar Afeyan | MRNA | Stock Option (Right to Buy) | Award | 12,908 | 12,908 | 06 May 2026 | Direct | |||
| Abbas Hussain | MRNA | Common Stock | Sale | -32% | $264,952 | $46.63 | -5,682 | 12,066 | 01 May 2026 | Direct |
| Sandra Horning | MRNA | Common Stock | Options Exercise | 690.2% | 16,233 | 18,585 | 30 Apr 2026 | Direct | ||
| Sandra Horning | MRNA | Restricted Stock Units | Options Exercise | -100% | -16,233 | 0 | 30 Apr 2026 | Direct | ||
| David M. Rubenstein | MRNA | Common Stock | Options Exercise | 531.5% | 8,116 | 9,643 | 30 Apr 2026 | Direct | ||
| David M. Rubenstein | MRNA | Restricted Stock Units | Options Exercise | -100% | -8,116 | 0 | 30 Apr 2026 | Direct | ||
| Abbas Hussain | MRNA | Common Stock | Options Exercise | 1071.5% | 16,233 | 17,748 | 30 Apr 2026 | Direct | ||
| Abbas Hussain | MRNA | Restricted Stock Units | Options Exercise | -100% | -16,233 | 0 | 30 Apr 2026 | Direct |
* marks a reported price that did not pass the local price check.